The World Health Organization (WHO) has recently made a significant update by including Cannabinoid Hyperemesis Syndrome (CHS) in its diagnostic manual. This decision came after the agency issued guidance in October, leading to the creation of a new dedicated code for the syndrome in the ICD-10 system. This move aims to provide more precise care for individuals struggling with CHS, a condition characterized by prolonged and severe episodes of uncontrolled vomiting in chronic cannabis users.
CHS has become a growing concern, prompting the CDC to adopt the WHO update to facilitate better diagnosis and monitoring of the syndrome. Previously categorized as a gastrointestinal disorder, CHS is now recognized as a distinct condition, allowing healthcare providers to offer more targeted treatment and conduct thorough studies on the disorder’s prevalence and impact.
Recent studies have highlighted a concerning trend in CHS-related emergency department visits, especially during the COVID-19 pandemic. The increased stress, isolation, and availability of high-potency cannabis products have contributed to a surge in CHS cases, leading to a spike in ED visits, particularly among young adults aged 18 to 35. The potency of THC in cannabis products has steadily risen over the years, with some products containing as much as 90% THC, posing a significant public health risk.
A study published in JAMA Network Open revealed a substantial increase in CHS-related ED visits among teenagers in recent years, emphasizing the need for greater awareness and prevention strategies. Dr. Andrew Meltzer, a prominent emergency medicine expert, highlighted the economic and public health burden posed by CHS, urging users to recognize the link between cannabis use and recurrent vomiting episodes.
Treatment for CHS often involves abstinence from cannabis, though weaning off the substance can be challenging for chronic users. A combination of cognitive behavioral therapy, motivational enhancement therapy, and medication may be necessary to address both the physical and psychological aspects of dependence. While novel approaches are being explored, no FDA-approved medications currently exist for treating Cannabis Use Disorder (CUD).
Overall, the recognition of CHS by global health authorities represents a step forward in addressing the complexities of cannabis-related health issues. By raising awareness, implementing preventive measures, and offering tailored treatment options, healthcare providers can better support individuals affected by CHS and promote overall well-being.
